The 20th AIFD Ordinary General Assembly was held
30.04.2025
The 20th Ordinary General Assembly Meeting of the Association of Research-Based Pharmaceutical Companies (AIFD), which operates with the mission of ensuring timely and sustainable access to innovative medicines and treatments in Türkiye, was held on April 21st. Cem Öztürk was re-elected as Chairman of the AIFD Board of Directors.
For the upcoming new term, the AIFD Board of Directors will be comprised of Cem Öztürk, Cenk Balcı, Ece Kaşıkçı, Erçin Kuğu, Laetitia Decroix Guilloux, Metin Hullu, Natacha Theytaz, Okan Güner, Şehram Zayer, Serkan Barış, and Sririam Jambunathan. The elected Board of Auditors members are Emre Kara, Muhittin Bilgütay, and Derya Köker, while Colin Tyrer and Nura Aykanat were appointed as members of the AIFD High Advisory Board. Cem Öztürk was re-elected as Chairman at the first board meeting.
Speaking at the General Assembly, AIFD Chairman Cem Öztürk stated: “As the Association of Research-Based Pharmaceutical Companies, we remain steadfast in our commitment to enhancing access to innovative medicines in Türkiye and contributing to the sustainable growth of the healthcare ecosystem. With our newly elected board, we will continue to strongly support efforts to improve patients’ access to innovative treatments. We will also work to strengthen collaboration between the public sector, private industry, and academia to enhance Türkiye’s expertise in pharmaceutical R&D and elevate its global competitiveness. With a clear understanding that healthcare is a strategic priority for our society, we will continue to contribute to strengthening our healthcare ecosystem and aligning our national healthcare capabilities with the standards of the most advanced countries.”